US 11,987,792 B2
Compositions and methods for inhibiting expression of the LECT2 gene
Gregory Hinkle, Plymouth, MA (US); and Huilei Xu, Cambridge, MA (US)
Assigned to ALNYLAM PHARMACEUTICALS, INC., Cambridge, MA (US)
Appl. No. 17/268,206
Filed by ALNYLAM PHARMACEUTICALS, INC., Cambridge, MA (US)
PCT Filed Aug. 15, 2019, PCT No. PCT/US2019/046657
§ 371(c)(1), (2) Date Feb. 12, 2021,
PCT Pub. No. WO2020/037125, PCT Pub. Date Feb. 20, 2020.
Claims priority of provisional application 62/764,909, filed on Aug. 16, 2018.
Prior Publication US 2021/0348162 A1, Nov. 11, 2021
Int. Cl. C12N 15/113 (2010.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/51 (2006.01); A61K 31/7125 (2006.01); A61K 47/02 (2006.01); C07H 21/02 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/5123 (2013.01); A61K 47/02 (2013.01); C12N 2310/14 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/351 (2013.01); C12N 2310/3515 (2013.01); C12N 2320/32 (2013.01); C12N 2320/35 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of LECT2, wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a LECT2 RNA transcript, wherein the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the antisense sequence and all the modifications of SEQ ID NO: 93 or 290 and the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the sense sequence and all the modifications of SEQ ID NO: 92 or 289.